Itraconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Itraconazole: From Antifungal Therapy to Pneumocystosis
One-Sentence Summary
Itraconazole is a triazole antifungal agent used systemically to treat and prevent invasive fungal infections. The TxGNN model predicts it may be effective against pneumocystosis (Pneumocystis jirovecii pneumonia), but this prediction is currently supported only by indirect literature — no clinical trials directly test itraconazole for this indication, and the underlying mechanistic rationale is considered weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no Taiwan/Germany licence data (drug is unmarketed); itraconazole is generally known as a systemic triazole antifungal |
| Predicted New Indication | Pneumocystosis (Pneumocystis jirovecii pneumonia) |
| TxGNN Prediction Score | 99.34% (rank 7232) |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for itraconazole is not available in this evidence pack (original_moa: [Data Gap]). Based on known pharmacology, itraconazole inhibits fungal CYP51 and blocks ergosterol synthesis — the classic mode of action for triazole antifungals, effective against dimorphic and mould pathogens (e.g. Histoplasma, Aspergillus).
However, Pneumocystis jirovecii has atypical membrane sterol metabolism compared with conventional fungi, and clinically it responds poorly to azole antifungals. Standard first-line therapy for pneumocystosis (TMP-SMX, pentamidine) does not include any triazole agent. The literature evidence identified here largely reflects itraconazole's role as broad-spectrum antifungal prophylaxis in immunocompromised populations (HIV, transplant recipients) where pneumocystosis is one of several co-occurring opportunistic infections — not direct evidence of anti-Pneumocystis activity.
Given this, the mechanistic basis for the prediction should be treated as an unvalidated hypothesis rather than an established pharmacological link, and further preclinical or in vitro activity data against P. jirovecii would be needed before further investment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11737382 | 2001 | RCT (Phase 3) | HIV Medicine | Double-blind, placebo-controlled trial of itraconazole capsules for prevention of deep fungal infections in HIV-infected patients — prophylactic context, not specific to pneumocystosis |
| 26036497 | 2015 | Cohort | Transplantation Proceedings | Single-centre experience of invasive fungal infections after kidney transplantation |
| 17594870 | 2007 | Cohort | Allergologia et Immunopathologia | 25-year experience of chronic granulomatous disease in paediatric patients, including fungal complications |
| 30429396 | 2018 | Cohort | Indian Journal of Medical Microbiology | Profile of respiratory fungal pathogens in immunocompetent vs immunocompromised hosts, correlated with CD4+ counts |
| 36891307 | 2023 | Case Report | Frontiers in Immunology | Talaromyces marneffei and Pneumocystis jirovecii coinfection in a child with STAT1 mutation |
| 2121456 | 1990 | Review | Drugs | Overview of therapy/prophylaxis for systemic protozoan and Pneumocystis carinii infections |
| 8397916 | 1993 | Review | Current Clinical Topics in Infectious Diseases | Prophylaxis and treatment of infection in bone marrow transplant recipients |
| 21418688 | 2010 | Review | BMJ Clinical Evidence | Primary and secondary prophylaxis for opportunistic infections in HIV |
| 8016481 | 1993 | Review | Seminars in Respiratory Infections | Infection (including fungal) after lung transplantation |
| 21973267 | 2011 | Review | Clinical Pharmacokinetics | Pulmonary epithelial lining fluid penetration of antifungal and other anti-infective agents |
Germany Market Information
Itraconazole is currently not marketed in Germany under the available regulatory data (0 authorizations recorded). No product/licence table can be generated.
Safety Considerations
Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications are marked as a Blocking data gap in this evidence pack and must be resolved before any safety evaluation can proceed — see Conclusion.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by indirect prophylaxis literature in immunocompromised populations, not by direct evidence of anti-Pneumocystis activity, and the proposed mechanism (ergosterol/CYP51 inhibition) is pharmacologically inconsistent with the atypical sterol biology of P. jirovecii. Combined with L5 evidence level (model prediction only) and a Blocking data gap on safety labelling, there is insufficient basis to advance.
To proceed, the following is needed:
- TFDA/manufacturer package insert (warnings, contraindications) — currently a Blocking gap
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Preclinical or in vitro evidence of itraconazole activity specifically against Pneumocystis jirovecii
- Any registered clinical trials evaluating itraconazole in pneumocystosis prevention/treatment, if they emerge
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.